People · Operator
Named in public records as an officer, director or promoter · active 2020–2020 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aridis Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $56.6M | $63.0M | 2020 |
Mike Nazak at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mike Nazak on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Isaac Blech | 1 | 14 |
| Robert Ruffolo | 1 | 8 |
| John Borgeson | 1 | 3 |
| John Hamilton | 1 | 3 |
| Robert Coughlin | 1 | 2 |
| Craig Gibbs | 1 | 2 |
| John K. Hamilton | 1 | 1 |
| Robert R. Ruffolo, Jr. | 1 | 1 |
| Isaac R. Blech | 1 | 1 |
| Craig K. Gibbs | 1 | 1 |
| Susan Windham-Bannister | 1 | 1 |
| Robert Ruffolo, Jr. | 1 | 1 |
| Vu Troung | 1 | 1 |
| Vu Truong | 1 | 1 |
| Fred Kurland | 1 | 1 |
| Eric Patzer | 1 | 1 |
| Paul-Andre De Lame | 1 | 1 |
| Robert K. Coughlin | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.